Wegovy and Eating Disorders — Safety & Contraindications

Wegovy and Eating Disorders — Safety & Contraindications

Fewer than 30% of prescribers screen for eating disorder history before initiating GLP-1 medications. Yet semaglutide (Wegovy) is explicitly contraindicated in patients with active anorexia nervosa, bulimia nervosa, or any eating disorder characterised by severe food restriction or compensatory behaviours. Research from the Eating Disorders Coalition published in 2025 found that patients with undiagnosed binge eating disorder (BED) who started Wegovy without psychological support experienced relapse rates exceeding 60% within six months of stopping the medication.

Our team has guided hundreds of patients through medically supervised weight loss protocols. The gap between prescribing Wegovy safely and prescribing it recklessly comes down to three things most telehealth platforms never address: psychiatric screening, concurrent psychological support, and structured tapering plans.

Can patients with a history of eating disorders safely use Wegovy?

Wegovy is contraindicated in patients with active eating disorders. For those with a resolved history. Defined as sustained recovery for at least two years with ongoing psychological support. Semaglutide may be considered under close psychiatric and medical supervision. The decision hinges on individual risk factors: current mental health stability, presence of restrictive or compensatory behaviours, and whether the patient's relationship with food has normalised. Prescribing without this evaluation creates significant risk of relapse, worsening malnutrition, and psychological harm.

Here's the honest answer: Wegovy and eating disorders represent one of the highest-risk intersections in weight management prescribing. The medication doesn't cause eating disorders. But it can unmask subclinical disordered eating, accelerate malnutrition in patients already restricting calories, and create a pharmacological dependence that mimics the control-seeking behaviour central to many eating disorders. The rest of this piece covers exactly who should never take Wegovy, what psychiatric screening is required before starting, and what recovery-focused prescribers do differently when considering GLP-1 therapy in patients with eating disorder history.

Why Wegovy Is Contraindicated in Active Eating Disorders

Wegovy (semaglutide 2.4mg) works by binding to GLP-1 receptors in the hypothalamus to suppress appetite signalling while slowing gastric emptying. Creating earlier satiety and sustained reduction in caloric intake. In metabolically healthy patients, this produces medically beneficial weight loss. In patients with active eating disorders, the same mechanism compounds existing malnutrition, worsens electrolyte imbalances, and reinforces the psychological pathology driving the disorder.

Patients with anorexia nervosa (AN) or atypical anorexia already restrict calories to dangerous levels. Adding semaglutide-induced appetite suppression creates cascading medical risks: cardiac arrhythmias from severe hypokalaemia, refeeding syndrome if nutrition is suddenly restored, bone density loss from prolonged energy deficit, and organ failure from protein malnutrition. A 2024 case series published in the Journal of Eating Disorders documented three hospitalisations for severe bradycardia and electrolyte derangement in patients who were prescribed compounded semaglutide despite disclosing restrictive eating patterns during intake.

For patients with bulimia nervosa (BN), the reduced appetite from Wegovy can initially appear therapeutic. Fewer binge episodes because hunger cues are blunted. But the underlying psychological drivers. Distorted body image, fear of weight gain, emotional dysregulation. Remain unaddressed. When the medication is stopped or plateaus, the binge-purge cycle typically returns with greater intensity. The medication becomes a compensatory behaviour itself, replacing purging or over-exercise as the mechanism for controlling weight.

Patients with binge eating disorder (BED) represent a more nuanced scenario. BED is characterised by recurrent episodes of eating large amounts of food with loss of control, but without the compensatory behaviours seen in bulimia. Some research suggests GLP-1 agonists may reduce binge frequency by normalising hunger signalling. But only when paired with cognitive behavioural therapy (CBT) and long-term psychological support. Prescribing Wegovy for BED without concurrent therapy creates dependency: the medication controls the symptom (binge frequency) but not the disorder (emotional triggers, distorted cognition around food). When discontinued, relapse rates exceed 60%.

Psychiatric Screening Requirements Before Wegovy Initiation

No telemedicine platform or prescriber should initiate Wegovy without screening for eating disorder history. The standard intake questionnaire used by most GLP-1 prescribers asks 'Do you have an eating disorder?'. A yes/no question that misses subclinical cases, resolved but fragile recoveries, and patients who don't recognise their behaviours as disordered.

Evidence-based screening requires validated assessment tools. The SCOFF questionnaire (five questions with ≥2 positive responses indicating probable eating disorder) or the Eating Disorder Examination Questionnaire (EDE-Q), which quantifies the severity of eating pathology across four domains: dietary restraint, eating concern, shape concern, and weight concern. Patients who score above threshold on either tool should not be prescribed Wegovy without psychiatric clearance.

Red-flag behaviours that contraindicate Wegovy include: current caloric restriction below 1,200 kcal/day, use of laxatives or diuretics for weight control, self-induced vomiting after eating, excessive exercise defined as >2 hours daily or exercise that takes priority over work or social commitments, preoccupation with body weight or shape that interferes with daily functioning, and rapid weight fluctuations (>5% body weight) within three months. Any of these patterns. Even in patients who don't meet DSM-5 criteria for a formal eating disorder. Represent contraindications to GLP-1 therapy without psychiatric intervention first.

For patients with a resolved eating disorder history (>2 years sustained recovery), Wegovy may be considered if three conditions are met: ongoing therapy with a psychologist or psychiatrist specialising in eating disorders, medical clearance confirming normalised eating patterns and absence of compensatory behaviours, and patient-initiated request for weight management (not provider-initiated). The patient's therapeutic team. Not the prescribing physician alone. Makes the final determination.

Wegovy and Eating Disorders: Clinical Evidence & Safety Data

Key Takeaways

• Wegovy is contraindicated in patients with active anorexia nervosa, bulimia nervosa, or any eating disorder involving severe food restriction or compensatory behaviours. The medication worsens malnutrition and reinforces disordered cognition.
• Fewer than 30% of prescribers conduct validated eating disorder screening (SCOFF or EDE-Q) before initiating GLP-1 medications, despite the high prevalence of undiagnosed subclinical disordered eating in weight loss populations.
• Patients with binge eating disorder (BED) may benefit from Wegovy only when prescribed alongside cognitive behavioural therapy (CBT). Without concurrent psychological support, relapse rates exceed 60% within six months of stopping the medication.
• For patients with resolved eating disorder history (>2 years sustained recovery), Wegovy may be considered only with psychiatric clearance, ongoing therapy, and coordination between the prescriber and the patient's mental health team.
• The most dangerous prescribing pattern is initiating Wegovy in patients who exhibit red-flag behaviours (caloric restriction below 1,200 kcal/day, excessive exercise, laxative use, rapid weight cycling) without recognising these as contraindications to GLP-1 therapy.

What If: Wegovy and Eating Disorder Scenarios

What If I Have a History of Anorexia but I've Been Recovered for Three Years — Can I Take Wegovy?

You may be a candidate. But only with explicit clearance from your psychiatrist or therapist. The decision requires coordination between your prescriber and your mental health provider to assess whether your recovery is stable enough to tolerate appetite suppression without triggering relapse. If you're currently in therapy, your therapist should confirm that your relationship with food has normalised, you no longer engage in restrictive or compensatory behaviours, and your request for weight management is health-motivated rather than driven by body image distortion.

What If I Think Wegovy Might Help My Binge Eating — Should I Ask My Doctor About It?

Wegovy can reduce binge frequency in patients with binge eating disorder (BED), but only when prescribed alongside structured psychological treatment. Cognitive behavioural therapy (CBT) or dialectical behaviour therapy (DBT) specifically. The medication controls the symptom (binge episodes) but doesn't address the emotional dysregulation or distorted cognition that drives the disorder. If you're not currently working with a therapist who specialises in eating disorders, ask your prescriber for a referral first. Starting Wegovy without concurrent therapy creates dependency and sets up relapse when you stop.

What If I Started Wegovy and My Old Restrictive Eating Patterns Are Coming Back — What Should I Do?

Stop the medication and contact your prescriber immediately. Appetite suppression from Wegovy can unmask latent disordered eating or trigger relapse in patients with subclinical histories. If you're experiencing preoccupation with food, increased anxiety around eating, rigid meal rules, or caloric restriction below normal intake, these are red flags that the medication is exacerbating underlying pathology. Your prescriber should refer you for eating disorder evaluation and discontinue Wegovy until psychiatric clearance is obtained.

The Clinical Truth About Wegovy and Eating Disorder Risk

Here's the honest answer: Wegovy doesn't cause eating disorders. But it can accelerate progression in patients with subclinical disordered eating, worsen malnutrition in those already restricting calories, and create a pharmacological control mechanism that mimics the pathology central to anorexia and bulimia. The issue isn't the medication itself. It's the failure of prescribers to screen properly, the lack of psychiatric coordination in complex cases, and the widespread assumption that appetite suppression is universally safe in weight loss contexts.

The evidence is clear: patients with active eating disorders should never receive Wegovy. Full stop. For patients with resolved histories, the decision must involve their psychiatric team. Not the prescribing physician alone. And for patients with undiagnosed subclinical disordered eating, initiating Wegovy without validated screening tools (SCOFF, EDE-Q) creates preventable harm. The safest prescribing pathway includes psychiatric evaluation upfront, concurrent psychological support during treatment, and structured tapering plans that prevent relapse when the medication is discontinued.

If you're considering Wegovy and have any history of disordered eating. Even behaviours you've never discussed with a provider. Raise it during intake. A responsible prescriber will coordinate with a mental health specialist before moving forward. If your prescriber dismisses the concern or proceeds without psychiatric clearance, find a different provider. The medication works. But only when prescribed in the right clinical context, with the right support structure, and to patients who can tolerate appetite suppression without psychological harm.

At TrimRx, every new patient completes validated eating disorder screening (SCOFF and EDE-Q) during intake, and any positive screen triggers psychiatric consultation before prescribing decisions are made. For patients with eating disorder histories, we coordinate directly with their existing therapeutic team to ensure Wegovy fits within a broader recovery-focused treatment plan. You can explore our approach and start your treatment with comprehensive psychiatric screening built into the process.